SeaStar Medical Announces First Shipment of QUELIMMUNE™-Pediatric to U.S. Partner Nuwellis, Inc.

DENVER – On July 12, 2024, SeaStar Medical Holding Corporation (ICU), a pioneering healthcare enterprise, proudly announced the departure of its inaugural commercial consignment of the QUELIMMUNE™-Pediatric range. This initial batch is destined for its American licensing and distribution collaborator, Nuwellis, Inc. (NUWE).

Revolutionizing Pediatric Critical Care

SeaStar Medical's QUELIMMUNE™ stands out as a groundbreaking Selective Cytopheretic Device (SCD). This novel offering is tailored to cater to the delicate needs of the pediatric population facing critical health conditions. QUELIMMUNE™-Pediatric aims to enhance the survival and recovery rates amongst these vulnerable patients by leveraging innovative medical technologies that SeaStar Medical has been refining.

Nuwellis, Inc.: A Strategic U.S. Distribution Channel

Headquartered in Eden Prairie, Minnesota, Nuwellis, Inc. (NUWE), is not merely a medical device company. It symbolizes a beacon of hope for countless individuals in need of advanced ultrafiltration therapy. As SeaStar Medical's choice for a U.S. distribution partner, Nuwellis, Inc. is set to play a pivotal role in making the QUELIMMUNE™-Pediatric available to medical facilities across the nation, thereby underscoring its commitment to enhancing patient care and outcomes.

Implications for Investors

The partnership between SeaStar Medical and Nuwellis, Inc. marks a formidable alliance in the healthcare industry, with potential ripple effects across the financial markets. Investors and shareholders of SeaStar Medical (ICU) and Nuwellis, Inc. (NUWE) are eyeing this development with optimism, anticipating how the commercialization of QUELIMMUNE™-Pediatric may influence the companies' fiscal health and, by extension, their stock valuation in a competitive marketplace.

SeaStar, Nuwellis, QUELIMMUNE